Navigation Links
European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors
Date:3/5/2009

Schering-Plough Receives EU and US Approvals for Intravenous Formulation of Temozolomide As Well As EU Approval for Oral Temozolomide Sachet Presentation

KENILWORTH, N.J., March 5 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that the European Commission and the US FDA both approved the intravenous (IV) formulation of temozolomide as an alternative to the already approved oral form of the drug. Temozolomide is marketed as TEMODAL(R) in the EU and as TEMODAR(R) in the US. The EU Commission Decision was based on the positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) in November 2008. On January 22, 2009, the Commission approved a sachet packaging presentation for TEMODAL Capsules. This new presentation provides greater patient convenience and flexibility. On February 17, 2009, the Commission approved an IV formulation of TEMODAL. On February 27, 2009, Schering-Plough received approval from the US FDA for the TEMODAR IV formulation.

TEMODAL is a chemotherapy agent approved in the EU for treatment of patients with newly diagnosed glioblastoma multiforme (GBM) concomitantly with radiotherapy and subsequently as monotherapy, and for patients with malignant gliomas, such as GBM or anaplastic astrocytoma (AA), showing recurrence or progression after standard therapy. In the US, TEMODAR is approved for the treatment of adult patients with newly diagnosed GBM concomitantly with radiotherapy and then as maintenance treatment, as well as for refractory AA, i.e., patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine.

"TEMODAR is a well recognized, effective treatment for patients with newly diagnosed GBM. The newly approved IV formulation of TEMODAR provides
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. CorMatrix Cardiovascular Announces First European Implants of CorMatrix(R) ECM Technology(TM)
2. Winner Medical Receives European Patent Office Approval for PurCotton(TM) Production Method
3. Frost & Sullivan: Novel Diagnostics Methods Driving the European Cancer IVD Market Towards Early Detection and Prevention
4. Abbott Receives European Commission Clearance on Acquisition of Advanced Medical Optics
5. Eisai and Bial Announce Partnership Agreement for the European Commercialisation of the Novel Once Daily Anti-Epileptic Zebinix(R)
6. Rising Demand and Government Backing Fuel European Document Management Systems Market
7. Noteworthy Medical Systems, Inc. Secures Capital from Top European eHealth Provider and Closes on Merger with Strategic Partner
8. ECO 2009 -- The 17th European Congress on obesity
9. PAREXEL Consulting Enhances European Regulatory Affairs Capabilities With Appointment of Medical Products Agency Expert Dr. Anders Neil
10. Global Economic Meltdown - Is the European Cardiac Rhythm Management Market Spared?
11. BeneChill Launches European Study of Intra-Arrest Cooling
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... Today, Zane Benefits, the #1 Online Health Benefits ... radio show. , According to Zane Benefits, health ... doesn’t make sense to choose a “one size fits ... and employee as much as 60 percent on health ... Speaking on Business , Chris Redgrave, highlights the rising ...
(Date:9/15/2014)... UC San Francisco researchers have used brain scans to ... a possible tool to spot children with dyslexia and ... , In the United States, children usually learn to ... proficient readers by third grade, according to the authors. ... kindergarteners as they were learning to read formally at ...
(Date:9/15/2014)... from the prospective Prostate, Lung, Colorectal and Ovarian (PLCO) ... baldness affecting both the front and the crown of ... increased risk of developing aggressive prostate cancer (usually indicates ... to non-aggressive prostate cancer) later in life, compared to ... between other patterns of baldness and prostate cancer risk. ...
(Date:9/15/2014)... 2014 In order to provide predictability ... act conjointly to quantify, define and model medical practice. ... integral part of medical care. , The Journal of ... conducted by the non-profit Institute of BioAcoustic Biology, located ... math can be much more than a measurement tool; ...
(Date:9/15/2014)... Amy Norton HealthDay ... A relatively small number of medications are responsible for sending ... a U.S. government study finds. Each year between 2007 ... were hospitalized after getting a hold of family members, medication, ... "Three-quarters of those children were just 1 or ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Featured on Zions Bank Speaking on Business 2Health News:Study first to use brain scans to forecast early reading difficulties 2Health News:Certain form of baldness at age 45 linked to higher risk of aggressive prostate cancer 2Health News:Math as Medicine: The Promise of Frequency Domain BioMarkers as a Template to Predict, Enchance and Promote Optimal Health 2Health News:Math as Medicine: The Promise of Frequency Domain BioMarkers as a Template to Predict, Enchance and Promote Optimal Health 3Health News:Small Number of Drugs Behind Kids' Accidental Poisonings: CDC 2Health News:Small Number of Drugs Behind Kids' Accidental Poisonings: CDC 3
... survival rate of non-small-cell lung cancer patients after ... Cisplatin is an anti-neoplastic medication that interferes with ... growth and spread in the body. ... three or four cycles of cisplatin-based chemotherapy or ...
... the world's first epilepsy drug, an Australian neurologist says.// ... a mild sedative, taken either as a herbal infusion ... form. ,But the Italian author Fabio Colonna first ... botanical work Phytobasanos. ,Colonna said he had controlled ...
... around 700,000 people researchers say dads who have children ... // for developing schizophrenia later in life. ... to the hospital in Sweden between 1989 and 2001 ... Researchers say they found a strong association between the ...
... recent study shows that people who use stomach-acid suppressive ... may be at an increased risk of developing pneumonia ... the stomach can increase vulnerability to infections, as stomach ... Researchers studied pneumonia rates of more than 364,000 patients ...
... study researchers say they have found that the drug ... cancer // decreased patients' cancer incidence after 12 months ... some impact, but the 20-milligram dose had the greatest ... prostatic intraepithelial neoplasia, characterized by abnormal cells in the ...
... New research shows that sleep disorders may be linked ... ADD ), // neuromuscular conditions, and psychiatric problems. ... patients with sleep apnea also had ADD. Results also ... insomnia. Further testing showed some of these patients also ...
Cached Medicine News:Health News:Valerian was first epilepsy drug 2
(Date:9/15/2014)... , Sept. 15, 2014 /PRNewswire-iReach/ -- Asthma ... persons of all ages, but most commonly starts ... characterized by narrowing of the airways, leading to ... lungs come into contact with endogenous and exogenous ... events, such as swelling of the airways, tightening ...
(Date:9/15/2014)... MedicOne Medical Response, a leading provider emergency and ... Inc. Magazine as one of the fastest growing ... - http://photos.prnewswire.com/prnh/20140914/145997 The ... with the largest revenue growth between 2010 and ... ambulance companies to make the list, achieved an ...
(Date:9/15/2014)... -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ... 2014, regular quarterly dividend payment of $0.15 per share ... September 5, 2014, the record date. About ... of patents and royalty assets, consisting primarily of its ... with various biotechnology and pharmaceutical companies. PDL pioneered the  ...
Breaking Medicine Technology:Asthma Market to Reach 161.02 million Cases in 10MM by 2023 2Asthma Market to Reach 161.02 million Cases in 10MM by 2023 3Asthma Market to Reach 161.02 million Cases in 10MM by 2023 4Asthma Market to Reach 161.02 million Cases in 10MM by 2023 5MedicOne Medical Response Named to 2014 Inc. 5000 Fastest Growing Companies List 2MedicOne Medical Response Named to 2014 Inc. 5000 Fastest Growing Companies List 3PDL BioPharma Completes Regular Quarterly Dividend Payment 2
... 11, 2011 Vanda Pharmaceuticals Inc. (NASDAQ: ... Corporation, an affiliate of Vanda,s sublicensor Novartis Pharma ... the long-acting injectable (or depot) formulation of Fanapt® ... will evaluate the safety and pharmacokinetic profiles of ...
... 11, 2011 Merck (NYSE: MRK ), ... and Intercell AG (VSE: ICLL) today announced that following ... trial evaluating V710, an investigational vaccine for the prevention ... Monitoring Committee (DMC) recommended suspension of enrollment. Although the ...
Cached Medicine Technology:Vanda Pharmaceuticals Announces Commencement of Clinical Study of Long-Acting Injectable Formulation of Fanapt® 2Vanda Pharmaceuticals Announces Commencement of Clinical Study of Long-Acting Injectable Formulation of Fanapt® 3Update on Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710 2Update on Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710 3
...
...
... exercise BP monitor is designed to automatically ... diastolic BP along with heart rate. It's ... use in treadmill, ergometer and pharmacological stress ... use in research environments., ,Tango excels ...
...
Medicine Products: